Ruikang pharmaceutical: 2019 net profit loss of RMB 1.021 billion, provision for impairment of goodwill of RMB 2.24 billion

Today, Ruikang pharmaceutical released the 2019 annual performance express, with revenue of 35.333 billion yuan, an increase of 4.17% year-on-year; net profit attributable to shareholders of listed companies was - 1.021 billion yuan, a decrease of 231.06% year-on-year For the main reason of the decrease in profits, Ruikang pharmaceutical said that in 2019, most of the company's subsidiaries achieved profits, but the performance did not fully meet the expectations Based on the principle of prudence, it is estimated that the amount of goodwill impairment reserve for more than 90 asset groups in 2019 is about 2.24 billion yuan At the same time, Ruikang pharmaceutical said that the profit and loss of changes in fair value due to changes in derivative financial liabilities was about 550 million yuan, which had an impact on deferred income tax expenses of 138 million yuan; in addition, after the company ' Recovery and turnover In this period, we increased financing such as supply chain finance and asset securitization, resulting in an increase in financial costs The announcement shows that the above asset impairment loss will not have any impact on the cash flow of Ruikang pharmaceutical, nor will it affect the current main business of Ruikang pharmaceutical and the normal operation of the subsequent years Adorable adorable